Vireo Growth (VREOF) Liabilities and Shareholders Equity (2020 - 2026)
Vireo Growth (VREOF) posted Liabilities and Shareholders Equity of $928.8 million for Q1 2026, up 13.66% sequentially from $817.2 million in Q4 2025, and up 235.25% YoY from $277.0 million in Q1 2025.
Vireo Growth (VREOF) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Vireo Growth has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $928.8 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 235.25% year-over-year to $928.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 226.56% YoY) and the FY2025 annual result came in at $817.2 million, up 193.05% from the prior year.
- Liabilities and Shareholders Equity rose to $928.8 million in Q1 2026 per VREOF's latest filing, from $817.2 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $928.8 million in Q1 2026 and troughed at $158.6 million in Q1 2023.
- A 5-year average of $327.1 million and a median of $190.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity fell 4.68% in 2022, then soared 250.19% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $159.2 million in 2022, then increased by 15.15% to $183.3 million in 2023, then jumped by 52.16% to $278.9 million in 2024, then surged by 193.05% to $817.2 million in 2025, then grew by 13.66% to $928.8 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $928.8 million, $817.2 million, and $678.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 6.18 Bn |
| 10 | Vireo Growth | 487.39 Mn | 345.09 Mn | 95.30 Mn | 1.27 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 928.80 Mn |
| Dec 31, 2025 | 817.20 Mn |
| Sep 30, 2025 | 678.92 Mn |
| Jun 30, 2025 | 659.34 Mn |
| Mar 31, 2025 | 277.05 Mn |
| Dec 31, 2024 | 278.86 Mn |
| Sep 30, 2024 | 193.87 Mn |
| Jun 30, 2024 | 194.68 Mn |
| Mar 31, 2024 | 190.88 Mn |
| Dec 31, 2023 | 183.26 Mn |
| Sep 30, 2023 | 171.67 Mn |
| Jun 30, 2023 | 165.95 Mn |
| Mar 31, 2023 | 158.63 Mn |
| Dec 31, 2022 | 159.16 Mn |
| Sep 30, 2022 | 173.32 Mn |
| Jun 30, 2022 | 168.82 Mn |
| Mar 31, 2022 | 160.73 Mn |
| Dec 31, 2021 | 166.97 Mn |
| Sep 30, 2021 | 164.16 Mn |
| Jun 30, 2021 | 112.68 Mn |